Hematology

The evolving treatment landscape for multiple myeloma includes debates on the timing and effectiveness of CAR T-cell therapy and quadruple immunotherapy regimens.

Disease-related factors include several prognostic scoring systems, such as DIPSS, whereas patient-related factors involve age, comorbidities, spleen size, and anemia.

Surprisingly, those with overweight BMI at diagnosis did not have a poor prognosis.

Optimizing outcomes for patients with chronic myeloid leukemia (CML) requires personalized treatment, adaptive dosing, and precise genetic insights.

Jose Tinajero, PharmD, BCOP, discusses the results of a retrospective study evaluating patients with B-cell acute lymphoblastic leukemia.

Pharmacists support treatment adherence as well as monitor adverse effects, drug-drug interactions, and quality of life.

In survivors of lymphoma with fragmented transition of care, preparedness and activation for the next phase of their survivorship was lacking.

Accurate, effective screening is crucial for connecting patients with needed financial resources and support.

Aligning with previous data, the drug combination was modestly effective in patients with large B-cell lymphoma pre- and post-CAR-T-cell therapy.

CAR T-cell therapy in multiple myeloma faces challenges from the immunosuppressive cells in the tumor microenvironment.

Building off the positive results of ELM-1, the ELM-2 trial found intravenously administered odronextamab was safe and effective in patients with relapsed or refractory follicular lymphoma.

This review explores cytopenia after CAR T-cell therapy, including its risk stratification and management with growth factors, thrombopoietin-receptor agonists, and hematopoietic stem cell boosts.

Pharmacists will play an integral role in this evolving field, from patient education and monitoring AEs to new therapeutic developments and treatment protocols.

A variety of signs and symptoms of lymphoma were reported, including fever, stomach discomfort, and weight loss.

Dan Schrum discusses the integral role of pharmacy specialists in translating clinical trial results to clinical practice.

Isatuximab (Sarclisa; Sanofi) in combination with standard-of-care significantly improved progression-free survival in patients with newly diagnosed multiple myeloma.

Dan Schrum highlights the crucial role of lymphodepletion in enhancing the effectiveness of CAR T cell therapy.

Denileukin diftitox-cxdl is the only therapy approved for cutaneous T-cell lymphoma that targets IL-2 receptors in malignant T-cells and Tregs.

Replacing carmustine with cisplatin in BEAM ((carmustine, etoposide, cytarabine, and melphalan) conditioning could be more cost-effective for patients.

Acalabrutinib plus venetoclax, with or without obinutuzumab, demonstrated significant improvements in progression-free survival.

Investigators determine the efficacy and safety of the combination in a 2-phase trial.

This is the first and only on-demand, virus-inactivated, human plasma-derived concentration option that is indicated for this approval.

The drug previously received breakthrough therapy designation for newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia that is in chronic phase.

Early identification of monoclonal gammopathy of undetermined significance leads to more efficacious disease monitoring and intervention.

Increased levels of absolute lymphocyte count are associated with improved response to BCMA-targeted CAR T-cell therapy.

The findings show that those with higher plasma homocysteine concentrations experienced more sleep apnea events per hour compared with those with lower concentrations.

Researchers identify significant proteins involved in the growth and survival of malignant multiple myeloma cells.

Omar Nadeem, MD, discusses positive outcomes associated with GPRC5D-targeted CAR T-cell therapy.

Chimeric antigen receptor (CAR) T-cell therapy can engineer T cells to target malignant cells in multiple myeloma.

Increased immunoglobulin replacement therapy led to reduced infections and managed secondary immune deficiencies such as hypogammaglobulinemia.